Company Pyxis Oncology, Inc.

Equities

PYXS

US7473241013

Biotechnology & Medical Research

Analysts' Consensus

Business Summary

Managers

Members of the board

Share class

Shareholders

Company contact information

Sector

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Bio Therapeutic Drugs

Market Closed - Nasdaq Other stock markets 21:00:00 10/05/2024 BST			5-day change	1st Jan Change
4.34 ^USD	-3.77%		-0.91%	+141.11%

03-22	H.C. Wainwright Adjusts Price Target on Pyxis Oncology to $7 From $4, Maintains Buy Rating	MT
03-21	Health Care Up on Drug Sales Optimism -- Health Care Roundup	DJ

Pyxis Oncology, Inc. is a clinical-stage company focused on developing therapeutics to target difficult-to-treat cancers. The Company is building therapeutics that hold the potential for mono and combination therapies. Its clinical program portfolio includes PYX-201, PYX-106 and PYX-107. PYX-201, an antibody-drug conjugate (ADC) that targets Extradomain-B Fibronectin within the tumor stroma, and PYX-106, a fully human Siglec-15-targeting antibody designed to block suppression of T-cell proliferation and function, are being evaluated in ongoing Phase 1 clinical studies in multiple types of solid tumors. PYX-107 is a CD40 agonist antibody designed to maximize its agonistic properties. Its therapeutic candidates are designed to directly kill tumor cells and to address the underlying pathologies created by cancer that enable its uncontrollable proliferation and immune evasion. Its ADC and immuno-oncology (IO) programs target a range of solid tumors resistant to current standards of care.

Number of employees: 50

Managers	Title	Age	Since
Lara Sullivan CEO	Chief Executive Officer	51	10/12/19
Pamela Connealy DFI	Director of Finance/CFO	63	30/06/21
Balu Balasubramanian CTO	Chief Tech/Sci/R&D Officer	-	-
Jan Pinkas CTO	Chief Tech/Sci/R&D Officer	-	31/07/21
Ken Kobayashi CTO	Chief Tech/Sci/R&D Officer	-	11-26
Jitendra Wadhane AUD	Comptroller/Controller/Auditor	44	31/07/21

Members of the board	Title	Age	Since
John Flavin FOU	Founder	55	10/06/18
Freda Lewis-Hall BRD	Director/Board Member	69	31/08/21
Darren Cline BRD	Director/Board Member	59	31/08/21
Jakob Dupont BRD	Director/Board Member	58	22/08/23
Rachel Humphrey BRD	Director/Board Member	62	10/08/22
Thomas Civik BRD	Director/Board Member	55	31/08/21
Lara Sullivan CEO	Chief Executive Officer	51	10/12/19

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	58,876,390	47,191,720 ( 80.15 %)	0	80.15 %

Name	Equities	%	Valuation
PFIZER, INC. 12.10 %	7,032,770	12.10 %	30 M $
Ridgeback Capital Management LLC 7.475 %	4,345,228	7.475 %	19 M $
Deep Track Capital LP 7.197 %	4,184,100	7.197 %	18 M $
Laurion Capital Management LP 5.454 %	3,170,803	5.454 %	14 M $
Lara Sullivan 3.211 %	1,866,547	3.211 %	8 M $
Vanguard Global Advisers LLC 2.411 %	1,401,425	2.411 %	6 M $
Pamela Connealy 1.910 %	1,110,293	1.910 %	5 M $
abrdn, Inc. 1.218 %	708,303	1.218 %	3 M $
Vestal Point Capital LP 0.7569 %	440,000	0.7569 %	2 M $
John Flavin 0.7105 %	413,015	0.7105 %	2 M $

Pyxis Oncology, Inc.

321 Harrison Avenue

02118, Boston

http://www.pyxisoncology.com

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

4.34 USD

Average target price

8 USD

Spread / Average Target

+84.33%

Consensus

Estimates Revisions

Company calendar

Healthcare

Pharmaceuticals & Medical Research

Biotechnology & Medical Research

Biotechnology & Medical Research

Bio Therapeutic Drugs

	1st Jan change	Capi.
PYXIS ONCOLOGY, INC.	+141.11%	256M
VERTEX PHARMACEUTICALS INCORPORATED	+3.91%	109B
REGENERON PHARMACEUTICALS, INC.	+10.87%	105B
ARGENX SE	+0.64%	22.25B
BIONTECH SE	-13.14%	22.09B
GENMAB A/S	-7.87%	18.68B
WUXI APPTEC CO., LTD.	-38.36%	17.58B
BEIGENE, LTD.	-10.66%	16.85B
NEUROCRINE BIOSCIENCES, INC.	+3.75%	13.76B
SAREPTA THERAPEUTICS, INC.	+36.70%	12.46B

Bio Therapeutic Drugs